Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 2,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $10,180.00. Following the completion of the transaction, the director owned 84,065 shares of the company's stock, valued at $427,890.85. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Mark Alvino also recently made the following trade(s):
- On Wednesday, January 21st, Mark Alvino sold 13,500 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.23, for a total value of $70,605.00.
- On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $4.74, for a total value of $71,100.00.
Abeona Therapeutics Stock Performance
NASDAQ:ABEO opened at $5.17 on Tuesday. Abeona Therapeutics Inc. has a twelve month low of $3.93 and a twelve month high of $7.54. The firm has a market cap of $280.16 million, a price-to-earnings ratio of 4.20 and a beta of 1.18. The company has a 50-day moving average of $5.16 and a 200-day moving average of $5.59. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. Analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts have issued reports on ABEO shares. Weiss Ratings reissued a "sell (d+)" rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, October 13th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $20.00.
View Our Latest Stock Analysis on ABEO
Institutional Trading of Abeona Therapeutics
A number of hedge funds have recently bought and sold shares of ABEO. AIGH Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $10,540,000. PVG Asset Management Corp acquired a new position in shares of Abeona Therapeutics in the 4th quarter worth approximately $66,000. Aberdeen Group plc acquired a new position in Abeona Therapeutics during the fourth quarter worth $3,248,000. SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics during the 4th quarter worth about $57,000. Finally, Sherbrooke Park Advisers LLC bought a new stake in Abeona Therapeutics during the third quarter worth about $64,000. 80.56% of the stock is owned by institutional investors.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
